UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 1, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At August 6, 2012, 7,469,483,622 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarterly Period Ended

July 1, 2012

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 1, 2012 and July 3, 2011

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2012 and July 3, 2011

Condensed Consolidated Balance Sheets as of July 1, 2012 and December 31, 2011

Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2012 and July 3, 2011

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

44

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

45

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

84

Item 4.

Controls and Procedures

84

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

84

Item 1A.

Risk Factors

85

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

86

Item 3.

Defaults Upon Senior Securities

86

Item 4.

Mine Safety Disclosures

86

Item 5.

Other Information

86

Item 6.

Exhibits

86

Signature

87

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 1,

2012

July 3,

2011

July 1,

2012

July 3,

2011

Revenues

15,057

16,485

29,942

32,509

Costs and expenses:

Cost of sales(a)

2,752

3,571

5,497

7,040

Selling, informational and administrative expenses(a)

3,977

4,800

7,954

9,178

Research and development expenses(a)

1,699

2,231

3,753

4,311

Amortization of intangible assets

1,291

1,384

2,711

2,749

Restructuring charges and certain acquisition-related costs

190

478

787

1,368

Other deductions net

664

423

2,321

1,255

Income from continuing operations before provision for taxes on income

4,484

3,598

6,919

6,608

Provision for taxes on income

1,290

1,077

2,001

1,951

Income from continuing operations

3,194

2,521

4,918

4,657

Discontinued operations net of tax

66

97

145

195

Net income before allocation to noncontrolling interests

3,260

2,618

5,063

4,852

Less: Net income attributable to noncontrolling interests

16

20

Net income attributable to Pfizer Inc.

3,253

2,610

5,047

4,832

Earnings per common share basic:(b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.43

0.32

0.65

0.58

Discontinued operations net of tax

0.01

0.01

0.02

0.02

Net income attributable to Pfizer Inc. common shareholders

0.44

0.33

0.67

0.61

Earnings per common share diluted:(b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.42

0.32

0.65

0.58

Discontinued operations net of tax

0.01

0.01

0.02

0.02

Net income attributable to Pfizer Inc. common shareholders

0.43

0.33

0.67

0.61

Weighted-average shares Basic

7,476

7,875

7,506

7,929

Weighted-average shares Diluted

7,537

7,935

7,570

7,980

Cash dividends paid per common share

0.22

0.20

0.44

0.40

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

(b)

EPS amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

July 1,

2012

July 3,

2011

July 1,

2012

July 3,

2011

Net income before allocation to noncontrolling interests

3,260

2,618

5,063

4,852

Other Comprehensive Income/(Loss)

Foreign currency translation adjustments

(1,981

956

(1,718

2,546

Reclassification adjustments(a)

(7

(1,981

956

(1,718

2,539

Unrealized holding gains/(losses) on derivative financial instruments

(657

228

(230

535

Reclassification adjustments for realized (gains)/losses(a)

427

(224

127

(734

(230

(103

(199

Unrealized holding gains/(losses) on available-for-sale securities

12

17

92

(20

Reclassification adjustments for realized (gains)/losses(a)

16

(1

33

28

16

125

(11

Benefit plans: Actuarial gains/(losses)

(505

(504

Reclassification adjustments related to amortization(b)

113

70

230

140

Reclassification adjustments related to curtailments and settlements, net(b)

(8

122

112

173

Other

39

(57

54

(144

(361

138

(108

172

Benefit plans: Prior service credits and other

26

26

Reclassification adjustments related to amortization(b)

(17

(17

(36

(35

Reclassification adjustments related to curtailments and settlements, net(b)

(73

(22

(82

(33

Other

(1

(2

(4

(64

(40

(94

(71

Other comprehensive income/(loss), before tax

(2,608

1,074

(1,898

2,430

Tax benefit on other comprehensive income/(loss)(c)

(205

(32

(1

(60

Other comprehensive income/(loss) before allocation to noncontrolling interests

(2,403

1,106

(1,897

2,490

Comprehensive Income

Comprehensive income before allocation to noncontrolling interests

857

3,724

3,166

7,342

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(10

12

(2

28

Comprehensive income attributable to Pfizer Inc.

867

3,712

3,168

7,314

(a)

Reclassified into Other deductions net in the condensed consolidated statements of income.

(b)

Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate in the condensed consolidated statements of income.

(c)

See Note 5B. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

July 1,

2012

Dec. 31,

2011

(Unaudited)

Assets

Cash and cash equivalents

3,031

3,182

Short-term investments

21,275

23,270

Accounts receivable, less allowance for doubtful accounts

12,882

13,058

Inventories

7,001

6,610

Taxes and other current assets

9,215

9,380

Assets of discontinued operations and other assets held for sale

5,361

5,317

Total current assets

58,765

60,817

Long-term investments

10,548

9,814

Property, plant and equipment, less accumulated depreciation

14,756

15,921

Goodwill

44,568

44,569

Identifiable intangible assets, less accumulated amortization

48,399

51,184

Taxes and other noncurrent assets

5,806

5,697

Total assets

182,842

188,002

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

7,703

4,016

Accounts payable

3,165

3,678

Dividends payable

1,826

1,796

Income taxes payable

2,098

1,009

Accrued compensation and related items

1,493

2,120

Other current liabilities

13,215

15,066

Liabilities of discontinued operations

1,298

1,224

Total current liabilities

30,798

28,909

Long-term debt

30,868

34,926

Pension benefit obligations

6,484

6,341

Postretirement benefit obligations

3,309

3,344

Noncurrent deferred tax liabilities

18,487

18,861

Other taxes payable

7,099

6,886

Other noncurrent liabilities

5,836

6,114

Total liabilities

102,881

105,381

Commitments and Contingencies

Preferred stock

42

45

Common stock

447

445

Additional paid-in capital

72,027

71,423

Employee benefit trusts

(2

(3

Treasury stock

(34,863

(31,801

Retained earnings

47,904

46,210

Accumulated other comprehensive loss

(6,008

(4,129

Total Pfizer Inc. shareholders equity

79,547

82,190

Equity attributable to noncontrolling interests

414

431

Total equity

79,961

82,621

Total liabilities and equity

182,842

188,002

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(millions of dollars)

July 1,

2012

July 3,

2011

Operating Activities

Net income before allocation to noncontrolling interests

5,063

4,852

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by operating activities:

Depreciation and amortization

4,002

4,353

Share-based compensation expense

247

244

Asset write-offs and impairment charges

758

573

Deferred taxes from continuing operations

(120

505

Other deferred taxes

14

(7

Benefit plan contributions in excess of expense

(20

(249

Other non-cash adjustments, net

(114

10

Other changes in assets and liabilities, net of acquisitions and divestitures

(3,035

259

Net cash provided by operating activities

6,795

10,540

Investing Activities

Purchases of property, plant and equipment

(548

(608

Purchases of short-term investments

(10,395

(6,559

Proceeds from redemptions and sales of short-term investments

14,357

4,643

Net proceeds from/(payments for) redemptions and sales of short-term investments with

original maturities of 90 days or less

(999

8,327

Purchases of long-term investments

(2,317

(3,193

Proceeds from redemptions and sales of long-term investments

304

1,572

Acquisitions, net of cash acquired

(782

(3,169

Other investing activities

(56

73

Net cash provided by/(used in) investing activities

(436

1,086

Financing Activities

Proceeds from short-term borrowings

3,764

4,868

Principal payments on short-term borrowings

(2

(2,483

Net payments on short-term borrowings with original maturities of 90 days or less

(4,146

(2,452

Principal payments on long-term debt

(7

(3,481

Purchases of common stock

(2,999

(3,679

Cash dividends paid

(3,283

(3,159

Other financing activities

198

64

Net cash used in financing activities

(6,475

(10,322

Effect of exchange-rate changes on cash and cash equivalents

(35

57

Net increase/(decrease) in cash and cash equivalents

(151

1,361

Cash and cash equivalents, beginning

3,182

1,735

Cash and cash equivalents, end

3,031

3,096

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

1,127

737

Interest

1,194

1,337

See Notes to Condensed Consolidated Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 27, 2012, and May 29, 2011. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to certain inventories (see Note 8. Inventories) and the reclassification of certain investments (see Note 7. Financial Instruments).

We anticipate filing a registration statement with the SEC by mid-August for a potential initial public offering (IPO) of up to a 20% ownership stake in our Animal Health business, Zoetis, Inc. (Zoetis). If the IPO is successfully completed, which we are targeting for the first half of 2013, we will have a variety of options to achieve a potential full separation of Zoetis. The Animal Health business continues to be presented as a continuing operation in these condensed consolidated financial statements.

On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl . As a result, beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. In addition, the assets and liabilities associated with this business are reported as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets (see Note 2B. Acquisitions and Divestitures: Divestitures). Prior period amounts have been restated.

On August 1, 2011, we completed the sale of our Capsugel business. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 3, 2011 (see Note 2B. Acquisitions and Divestitures: Divestitures).

As a result of our acquisition of King Pharmaceutical, Inc. (King) and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the six months ended July 3, 2011 reflect approximately five months of King s U.S. operations and approximately four months of King s international operations (for additional information, see Note 2A. Acquisitions and Divestitures: Acquisitions).

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and results of operations.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2011 Annual Report on Form 10-K.

B. Adoption of New Accounting Standards

The provisions of the following new accounting and disclosure standards were adopted as of January 1, 2012:

Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented separate Condensed Consolidated Statements of Comprehensive Income.

An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Note 2. Acquisitions and Divestitures

A. Acquisitions

Alacer Corp.

On February 26, 2012, we completed our acquisition of Alacer Corp., a privately owned company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this consumer healthcare acquisition, we recorded $247 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand, $94 million in net deferred tax liabilities and $151 million in Goodwill. The allocation of the consideration transferred has been finalized.

Ferrosan Holding A/S

On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Due to the fact that financial information included in our fiscal year 2011 consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30, this acquisition is reflected in our condensed consolidated financials beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this acquisition, we recorded $483 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands, $124 million in net deferred tax liabilities and $231 million in Goodwill. The allocation of the consideration transferred has not been finalized.

King Pharmaceuticals, Inc.

On January 31, 2011 (the acquisition date), we completed a tender offer for the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).

King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table provides the assets acquired and liabilities assumed from King:

(millions of dollars)

Amounts

Recognized as of

Acquisition Date

(Final)

Working capital, excluding inventories

155

Inventories

340

Property, plant and equipment

412

Identifiable intangible assets, excluding in-process research and development

1,806

In-process research and development

303

Net tax accounts

(328

All other long-term assets and liabilities, net

102

Total identifiable net assets

2,790

Goodwill(a)

765

Net assets acquired/total consideration transferred

3,555

(a)

Goodwill recorded as of the acquisition date totaled $720 million for our three biopharmaceutical operating segments and $45 million for our Animal Health and Consumer Healthcare operating segment. (Since the acquisition of King, we have revised our operating segments. See Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.)

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:

the expected synergies and other benefits that we believed would result from combining the operations of King with the operations of Pfizer;

any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and

the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for tax purposes (see Note 9A. Goodwill and Other Intangible Assets: Goodwill for additional information).

The assets and liabilities arising from contingencies recognized as of the acquisition date are not significant to Pfizer s condensed consolidated financial statements.

The following table provides the actual financial results of King included in the condensed consolidated statement of income:

(millions of dollars)

King s Operations

Included in Pfizer s

Six-Month

2011 Results

Revenues(a)

581

Loss from continuing operations attributable to Pfizer Inc. common shareholders(a), (b)

(74

(a)

From January 31, 2011 (the acquisition date) through Pfizer s second-quarter 2011 domestic and international quarter-ends.

(b)

Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($119 million pre-tax), amortization of identifiable intangible assets acquired from King ($71 million pre-tax) and restructuring and integration costs ($159 million pre-tax).

If the acquisition of King had occurred on January 1, 2011, the change to Pfizer s Revenues, Income from continuing operations attributable to Pfizer Inc. common shareholders and Diluted earnings per share attributable to Pfizer Inc. common shareholders would not have been material.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Divestitures

On April 23, 2012, we announced that we entered into an agreement to sell our Nutrition business to Nestl for $11.85 billion in cash. The transaction is expected to close by the first half of 2013, assuming the receipt of the required regulatory clearances and satisfaction of other closing conditions. Beginning in the second quarter of 2012, we report the operating results of the Nutrition business as Discontinued operations net of tax in the condensed consolidated statements of income for all periods presented. The transaction also includes the sale of certain prenatal multivitamins currently commercialized by the Pfizer Consumer Healthcare business unit. The operating results of this product line are also included in Discontinued operations net of tax for all periods presented. In addition, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the condensed consolidated balance sheets.

On August 1, 2011, we completed the sale of our Capsugel business for approximately $2.4 billion in cash. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended July 3, 2011.

The following table provides the components of Discontinued operations net of tax:

Three Months Ended

Six Months Ended

(millions of dollars)

July 1,

2012

July 3,

2011

July 1,

2012

July 3,

2011

Revenues(a)

581

714

1,101

1,369

Income from discontinued operations before provision for taxes

on income

119

128

237

263

Provision for taxes on income(b)

(53

(31

(92

(68

Discontinued operations net of tax(a)

66

97

145

195

(a)

Includes the Nutrition business for all periods presented and the Capsugel business for 2011 only.

(b)

Includes deferred tax expense (includes deferred taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries permanent in duration) of $22 million and a deferred tax benefit of $4 million for the three months ended July 1, 2012 and July 3, 2011, respectively, and a deferred tax expense of $14 million and a deferred tax benefit of $7 million for the six months ended July 1, 2012 and July 3, 2011, respectively.

The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations:

(millions of dollars)

July 1,

2012

Dec. 31,

2011

Accounts receivable, less allowance for doubtful accounts

559

550

Inventories

366

359

Prepaid assets

40

45

Current deferred tax assets and other current assets

44

15

Property, plant and equipment, less accumulated depreciation

1,138

1,118

Goodwill

495

498

Identifiable intangible assets, less accumulated amortization

2,620

2,648

Deposits advances and other assets

32

47

Deferred charges

21

23

Noncurrent deferred tax assets and other noncurrent assets

46

14

Assets of discontinued operations and other assets held for sale

5,361

5,317

Current liabilities

427

385

Other liabilities

871

839

Liabilities of discontinued operations

1,298

1,224

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for any period presented.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction and productivity initiatives. For example:

In connection with our cost-reduction and productivity initiatives, significant programs of which began in 2005, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company).

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as information technology, shared services and corporate operations.

Since the acquisition of Wyeth on October 15, 2009, our cost-reduction initiatives announced on January 26, 2009, but not completed as of December 31, 2009, were incorporated into a comprehensive plan to integrate Wyeth s operations to generate cost savings and to capture synergies across the combined company. In addition, on February 1, 2011, we announced a new productivity initiative to accelerate our strategies to improve innovation and productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

Six Months Ended